Patients with a history of gastrointestinal conditions such as acid reflux, irritable bowel syndrome, or gastroparesis should be especially cautious when starting GLP-1 medications
Has anyone else tried them
This is particularly helpful during dose escalation periods when side effects tend to peak
We specify no fill volume, as that is a protocol decision, and provide no dosing information
But as of today, Glucagon-Like peptide 1 receptor agonists (GLP1-RAs), sodium-glucose cotransporter 2 inhibitors (SGLT2is), dipeptidyl peptidase 4 inhibitors (DPP4is) and mineralocorticoid receptor antagonists, are quickly becoming part of, if not the drugs of choice for diabetes, especially in cases with heart, kidney or liver comorbidities [9,10,11,12]
Notably, no permanent treatment discontinuations or dose reductions due to gastrointestinal side effects were reported in ribupatide-treated participants